Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Regulation FD Disclosure

Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

Story continues below


Exhibit No. Description
10.1 Employment Agreement, dated July 27, 2017, by and between Anika Therapeutics, Inc. and Joseph G. Darling.
99.1 Press Release of Anika Therapeutics, Inc. dated July 27, 2017.

Anika Therapeutics, Inc. Exhibit
EX-10.1 2 a51597148ex10_1.htm EXHIBIT 10.1 Exhibit 10.1         EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) shall be effective as of the 27th day of July,…
To view the full exhibit click here

About Anika Therapeutics, Inc. (NASDAQ:ANIK)

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.

An ad to help with our costs